Point of care testing of aspirin resistance in patients with vascular disease

ANZ Journal of Surgery

Volumn 76, Issue 10, 2006, Pages 873-877

  Wong, Shen ^a,c   Ward, Christopher M ^a   Appleberg, Michael ^a   Lewis, David R ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Aspirin; Peripheral vascular disease; Platelet; Platelet aggregation inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; INTERNAL CAROTID ARTERY OCCLUSION; MALE; POINT OF CARE TESTING; PRESCRIPTION; THROMBOCYTE DYSFUNCTION; THROMBOSIS; VASCULAR DISEASE; VENOUS BLOOD;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; DRUG RESISTANCE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES;

EID: 33749120305     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2006.03693.x     Document Type: Article

References (36)

1. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br. J. Surg. 2001; 88: 787-800.
2. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. Br. Med. J. 1998; 316: 1303-9.
3. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970; 41: 875-83.
4. Ruckley CV. Claudication. Br. Med. J. 1986; 292: 970-71.
5. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 308: 81-106.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Br. Med. J. 1994; 308: 159-68.
7. Schweizer J, Kirch W, Koch R. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000; 51: 913-23.
8. Gum PA, Kottke-Marchant K, Welsh P, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 2003; 41: 961-5.
9. Eikelboom JW, Hirsh J, Weitz JI. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-55.
10. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 1991; 63: 587-93.
11. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 2005; 142: 370-80.
12. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001; 88: 230-35.
13. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
14. Mueller MR, Salat A, Stangl P et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb. Haemost. 1997; 78: 1003-7.
15. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch. Pathol. Lab. Med. 1994; 118: 801-4.
16. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur. J. Vasc. Endovasc. Surg. 2004; 27: 456-65.
17. Nicholson NS, Panzer-Nodle SG, Haas NF et al. Assessment of platelet function assays. Am. Heart J. 1998; 135: S170-78.
18. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-36.
19. Mammen EF, Comp PC, Gosselin R et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost. 1998; 24: 195-202.
20. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J. Lab. Clin. Med. 2001; 138: 152-63.
21. Harrison P, Robinson MS, Mackie IJ et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul. Fibrinolysis 1999; 10: 25-31.
22. Francis JL, Francis D, Larson L, Helms E, Garcia M. Can the platelet function analyser (PFA) - 100 substitute for the template bleeding time in routine clinical practice. Platelets 1999; 10: 132-6.
23. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am. J. Hematol. 1999; 62: 165-74.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002; 324: 71-86.
25. Alexander JH, Harrington RA, Tuttle RH et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: receptor suppression using integrilin therapy. Am. J. Cardiol. 1999; 83: 1147-51.
26. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. Cardiol. 1995; 11: 221-7.
27. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J. Am. Coll. Cardiol. 2003; 41: 966-8.
28. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand. Cardiovasc. J. 1998; 32: 233-7.
29. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br. J. Pharmacol. 2001; 134: 353-8.
30. Carcao MD, Blanchette VS, Stephens D et al. Assessment of thrombocytopenic disorders using the platelet function analyzer (PFA-100). Br. J. Haematol. 2002; 117: 961-4.
31. Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003; 34: 849-54.
32. Homoncik M, Jilma B, Hergovich N et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb. Haemost. 2000; 83: 316-21.
33. Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyser PFA-100. Blood Coagul. Fibrinolysis 2002; 12: 277-81.
34. von Pape KW, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb. Res. 2000; 98: 295-9.
35. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34: 849-54.
36. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.